Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619099 | 0.84 | MEN1 (0.64) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL1619448 | 0.80 | MEN1 (0.47) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL6234642 | 0.80 | IDO1 (0.52) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL1619199 | 0.77 | MAPT (0.48) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| Ethyl Acetate SCHEMBL1618946 | 0.74 | ALDH1A1 (0.47) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL1619250 | 0.74 | ALDH1A1 (0.54) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL27552546 | 0.72 | ALDH1A1 (0.53) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL7439749 | 0.72 | POLB (0.50) | MEN1KMT2AMAPTALDH1A1NPSR1 | |
| SCHEMBL2664334 | 0.70 | MAPT (0.48) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL27568970 | 0.69 | IDO1 (0.56) | MAPTALDH1A1NPSR1HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| EP-1951706-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | GCK, GCKR, GPR119 | MEN1 4197/4885KMT2A 2352/4885TDP1 2743/4885 |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | GCK, GCKR, GPR119 | MEN1 4167/4885KMT2A 2275/4885TDP1 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.